FR3078489A1 - CARTRIDGE FOR INJECTION DEVICE WITHOUT NEEDLE - Google Patents

Abstract

Cartridge (1) for injection device (100) without needle comprising: - at least a first chamber (5) containing and / or intended to receive a composition (C) to be injected, - at least one injection nozzle (6) ) communicating with the or each first chamber (5), the cartridge comprising a plurality of first chambers (5) and / or the cartridge comprising at least a second chamber (7) containing the composition (C) to be injected and communicating with the first one or the first chambers (5) by at least one supply duct (8) through which the supply of the first chamber or chambers (5) with the composition (C) contained in the or each second chamber (7).

Description

The present invention relates to a cartridge for a needle-less injection device, a needle-less injection system and a method of treatment, in particular cosmetic, of human keratin materials.

State of the art

The publications US 8876758 B2, US 9186461 B2, US 8066661 B2, US 20160129191 A1, US 8734384 B2 and US 9265888 B2 disclose needleless injectors comprising a reservoir containing a gas, a chamber containing a piston and a viscous liquid formulation to be injected, the chamber communicating with an injection nozzle.

Such needleless injectors require, once the chamber is empty, to be replaced or recharged, in particular manual, in order to be able to be used again.

Such needleless injectors have an injection nozzle whose geometry and dimensions are fixed, which limits the formulations that can be used, in particular in terms of viscosity. This can lead, on the one hand, to limitations on the treatments that can be carried out and, on the other hand, to a loss of formulation at the start of the injection.

For example, to treat wrinkles, different products are currently available on the market, such as hyaluronic acid or botox, which have different rheologies. Thus, the same injector without needle as described above does not allow the injection of these two products, the geometry and the dimensions of the injection nozzle, in particular the size of its outlet orifice, having to be adapted to the product. to inject.

There therefore remains a need to further improve the injection of a product into human keratin materials by an injector without a needle, in particular for preventing, treating and / or reducing a relief and / or a fold in a skin area and / or a skin color disorder.

Summary of the invention

The present invention aims to further improve the devices used to treat human keratin materials such as the skin, and in particular to remedy the above drawback. It does this using a cartridge for a needle-less injection device, comprising:

- at least one first chamber containing and / or intended to receive a composition to be injected,

at least one injection nozzle communicating with the or each first chamber, the cartridge comprising several first chambers and / or the cartridge comprising at least one second chamber containing the composition to be injected and communicating with the first chamber or chambers by at least one supply conduit through which the supply of the first chamber or chambers is carried out with the composition contained in the or each second chamber.

By "needle-less injection device" is meant a device in which the injection is carried out without penetration through the epidermis of an injection needle.

In one embodiment of the invention, the cartridge comprises a first chamber intended to receive a composition to be injected, an injection nozzle communicating with the first chamber and at least a second chamber containing the composition to be injected and communicating with the first chamber by at least one supply duct through which the first chamber is supplied with the composition contained in the second chamber. In the presence of a nozzle with several outlet channels, the arrangement of the outlet channels can follow the shape of the area to be treated, for example follow the shape of a wrinkle that one wishes to fill or of a spot that the 'we want to treat.

In a variant, the cartridge comprises several first chambers each containing a composition to be injected, and at least one injection nozzle communicating with each first chamber.

In another variant, the cartridge comprises several first chambers containing and / or intended each to receive a composition to be injected, at least one injection nozzle communicating with each first chamber, and at least a second chamber containing the composition to be injected and communicating with the first chambers by at least one supply duct, through which the first chambers are supplied with the composition contained in the second chamber.

In the presence of several first chambers, the outlet channels of the corresponding nozzles can follow, as in the case of a single first chamber, the shape of an area to be treated, for example a wrinkle.

The invention provides an easy-to-use, reliable, robust, compact and ergonomic solution for the needleless injection of a composition.

The cartridge according to the invention has the advantage of being ready to use and does not require any adjustment on the part of the user before use. It can be specifically dedicated, by its geometry and its dimensions, to a particular application. For example, the geometry and the dimensions of the first and second chambers and of the injection nozzle are adapted to the volume and to the nature of the composition to be injected, in particular its rheology, with a view to carrying out a given treatment.

The or each second chamber can constitute a multidose reservoir for the composition to be injected. The or each second chamber may also contain the composition to be injected in an amount sufficient to carry out an entire treatment session with several injections.

After injecting a dose of the composition contained in the first chamber, the latter can be recharged automatically with the composition contained in the or each second chamber, without the need to replace the cartridge. This reduces handling during processing.

By "skin" is meant the dermis and epidermis and the surface region of the mucous membranes such as the lips.

The cartridge can include several second chambers. Each second chamber can communicate with the or each first chamber by at least one supply duct. The second bedrooms can be arranged all around the first bedroom.

Preferably, in particular when the composition is pressurized in the first chamber for injection, the or each supply duct comprises a shutter, which is for example a ball. The latter can close the supply duct during the injection.

Preferably, the shutter is kept closed by the pressure in the first chamber during the injection and opens between two injections to allow the filling of the first chamber with the composition contained in the or each second chamber.

The cartridge can be supplied to the user with the first chamber or chambers pre-filled or not with a unit dose of the composition to be injected.

The pressurization of the or each first chamber can be carried out in various ways.

Preferably, the first chamber receives a first piston connected to a push rod, the first piston sliding along the longitudinal axis of the first chamber being driven by the push rod. The pressure exerted on this first piston during injection is sufficient to cause the composition to leave the outside of the cartridge. This pressure is in particular sufficient to cause the composition to at least partially penetrate the skin.

Preferably, the injection nozzle forms the distal end of the cartridge. The nozzle has at least one outlet channel, the or each outlet channel having an opening through which the composition to be injected is expelled to the outside.

Preferably, the first chamber, the second chamber, the injection nozzle and the supply duct are defined at least partially by a body formed in one piece. Such a one-piece construction can have increased strength and is easier to handle and use.

Preferably, the volume Vi of the first chamber is less than that V2 of the second chamber. This makes it possible to be able to supply or recharge, several times, the first chamber with the composition contained in the second chamber in order to be able to carry out several injections with the same cartridge. During an injection, all or part of the contents of the first chamber can be delivered to the user. In other words, the first chamber can be emptied at once during the injection, or alternatively several injections are made with the content of the first chamber before recharging it with product, if necessary.

The first chamber can be tubular. Its wall can converge at its distal end, in particular up to the outlet channel of the injection nozzle.

The second chamber can be annular in shape and extend around the first. A compact construction is thus obtained, and the communication between the two chambers can be carried out simply by a radial supply duct.

Preferably, the or each second chamber is closed at one of its axial ends by a second piston, in particular of annular shape, sliding along the longitudinal axis of the or each second chamber. This second piston can be pushed towards the distal end of the or each second chamber to empty the latter. The pressure can be exerted permanently, by a spring for example, or be exerted only when filling the first chamber.

The cartridge may include a third chamber arranged in the extension of the injection nozzle. This third chamber can be subjected to a pressure below atmospheric pressure. This makes it possible to increase, during the injection, the speed with which the composition is ejected from the nozzle in the direction of the skin, so as to allow the composition to at least partially penetrate the skin.

The composition can have various formulations and rheologies depending on the aim pursued.

Preferably, the composition is liquid and comprises a liquid phase, a mixture of a liquid phase and a pulverulent phase and / or a mixture of a liquid phase and a gaseous phase.

The liquid composition may have a viscosity greater than or equal to 10 Pa.s at 25 ° C and under atmospheric pressure.

The composition may be intended for the treatment and / or prevention of wrinkles, and comprise at least one filling agent, in particular a biopolymer such as hyaluronic acid and / or one of its salts, particles of hydroxyapatite, polylactic acid, alginate, sodium monomethyltrisilanol orthohydroxy benzoate, collagen, an acrylic polymer such as polyacrilamide, a methacrylic polymer and / or dextran microbubbles.

The composition may in particular comprise a liquid medium with particles in a state dispersed in the liquid medium, being solidifiable via the aggregation of said particles.

Preferably, the composition comprises at least one biopolymer, in particular an alginate, and an ionic solution, in particular a solution of a divalent ion.

The invention can make it possible to combat the cutaneous signs of aging and in particular to maintain and / or restore the viscoelastic or biomechanical properties of the skin, in order to improve the firmness, the elasticity, the tone of the skin and to prevent the appearance of skin signs of aging.

By “viscoelastic or biomechanical properties of the skin” in the context of the present invention, is meant the properties of stretch, tone, firmness, suppleness and / or elasticity of the skin.

By “cutaneous signs of aging” is meant all modifications of the external appearance of the skin due to aging, whether chronobiological and / or extrinsic, mainly photo-induced, such as for example wrinkles and fine lines, withered skin. , flabby skin, thinned skin, dull and dull skin, lack of elasticity and / or skin tone.

Alternatively, the invention is used to prevent, treat and / or reduce a skin color disorder. In examples of implementation of the invention, the composition is thus a composition for coloring the skin, comprising at least one coloring agent.

Preferably, the composition is cosmetic but, as a variant, it exerts a dermatological action.

Another subject of the invention, according to another of its aspects, is a needle-less injection system comprising a removable cartridge according to the invention, as defined above, and a needle-less injection device configured to receive said cartridge.

The cartridge can be arranged to be received in a housing of the injection device. Alternatively, the cartridge is configured to be removably attached, in particular by screwing or bayonet attachment, to the injection device.

This allows the user to easily change the cartridge according to their needs.

Preferably, the injection device comprises a first actuator for acting on the push rod received in the first chamber of the cartridge.

The device may comprise at least a second actuator, in particular of annular shape, to act on the second piston closing one of the ends of the second chamber.

Preferably, the actuators allowing the emptying of the first and second chambers are moved along the longitudinal axis of the device in the direction of the nozzle by drive means such as a source of compressed and / or liquefied gas.

Alternatively, these actuators are moved along the longitudinal axis of the device in the direction of the nozzle by other drive means such as a spring, a motor or an electromagnet.

Preferably, the device comprises at least one elastic return member making it possible to accompany or dampen the movement of the first piston in the first chamber and / or helping the latter to return to its initial position after injection.

The needleless injection system according to the invention may include an automatic recognition system of the treated area, configured to automatically determine the location and the depth of the area to be treated when the injection system is approached to the skin, and automatically adapt the injection parameters, in particular the injection depth. This system can generate information on the cartridge to be used and / or the pressure to be applied using the aforementioned drive means, so as to obtain the desired penetration into the skin.

Another subject of the invention is, according to another of its aspects, a method of treatment, in particular cosmetic, i.e. non-therapeutic, of human keratin materials, comprising the steps consisting in:

- have a cartridge containing a composition to be injected into a needle-less injection device so as to form a needle-less injection system according to the invention as defined above,

- approach the needle-less injection system of the human keratin materials to be treated,

- delivering, on each injection into said human keratin materials, an amount of the composition contained in the cartridge.

The method according to the invention may include the step of recharging the first chamber between two injections with a dose of composition taken from the second chamber of the cartridge.

The invention makes it possible in particular to inject the composition into the epidermis and / or the dermis. To act on the injection depth, one can act on the pressure in the first chamber and the speed with which the composition is ejected from the nozzle towards the skin.

Another subject of the invention is, according to another of its aspects, the cosmetic, ie non-therapeutic, use of a needle-less injection system according to the invention as defined above, for improving the appearance, especially aesthetic, of the skin.

In particular, the needle-less injection system according to the invention can be used to prevent, treat and / or reduce a relief and / or a fold in a skin area, in particular a fine line, wrinkle and / or scar.

Composition

The composition to be injected according to the invention is preferably liquid, at least at the time of its injection.

The composition may be a liquid phase, a mixture of a liquid phase and a pulverulent phase, a mixture of a liquid phase and a gaseous phase, or of a liquid, pulverulent and gaseous phase.

The viscosity is measured at 25 ° C and under 1 atm, with a Rhéomat 180 viscometer equipped with the MK-R-1, 2 or 3 mobile depending on the viscosity range and the corresponding measuring cup MB-R-1, 2 or 3 , at a rotation speed of 200 min ' ¹ , the measurement being carried out after 10 minutes of rotation (time after which a stabilization of the viscosity and of the speed of rotation of the mobile is observed).

The composition may have a viscosity greater than or equal to 10 Pa.s, at the time of its injection.

The composition according to the invention may include an oily phase. The fatty phase may in particular comprise oils, waxes or pasty fatty substances. By “pasty fatty substance” is meant a viscous product containing a liquid fraction and a solid fraction. Means in particular fatty substances having a melting point ranging from 20 to 55 ° C and / or a viscosity at 40 ° C ranging from 0.1 to 40 Pa.s (1 to 400 poises) measured with Contraves TV or Rheomat 180 .

The composition according to the invention may include an aqueous phase.

Preferably, the composition to be injected is sterile and biocompatible.

The composition to be injected can be a cosmetic composition, in which case it comprises a physiologically acceptable medium, that is to say a non-toxic medium capable of being injected into the skin of human beings.

The composition to be injected can also be dermatological.

Composition for treating and / or preventing a relief and / or a fold of a skin area

Fillers

As mentioned above, the composition according to the invention can comprise at least one filling agent.

The composition comprising at least one filling agent may or may not have the same rheology before and after injection into the skin. In particular, the composition may be more fluid at the time of its injection, and solidify or become more viscous in situ.

Preferably, the filling agent comprises at least one biopolymer.

Due to the mechanism of action of biopolymers and their injection thanks to the invention in quantities and depths within the skin which cannot be reached by the use of topical compositions, lasting and visible effects can to be obtained.

The filling agent can be absorbable or semi-absorbable. By "absorbable" is meant a filling agent which can dissolve completely within the skin in 3 to 6 months, and by "semi-absorbable", a filling agent which can dissolve completely in the skin by 6 to 24 months. These durations correspond to the duration of action of the filling agent. Alternatively, the filling agent is not absorbable.

The composition according to the invention can comprise at least one filling agent such as hyaluronic acid and / or one of its derivatives and / or one of its salts.

Preferably, the hyaluronic acid is crosslinked. Cross-linking makes it possible to form a cross-linked, rigid, elastic gel which hydrates and swells in water. Crosslinked hyaluronic acid is used for its filling properties, notably fine lines and / or wrinkles of the skin, due to the stiffness of the gel, as well as its highly viscoelastic properties and its high hydration power.

Hyaluronic acid can in particular be used in a mixture with lidocaine and / or dextran microbubbles.

The composition to be injected can be a solution from the BELOTERO® range sold by the company Merz, in particular the BELOTERO® Soft solution.

The composition according to the invention may comprise particles of hydroxyapatite, in particular of calcium, polylactic acid, an alginate, sodium monomethyltrisilanol orthohydroxy benzoate, collagen, an acrylic polymer such as polyacrylamide, a methacrylic polymer, and any mixture of the above compounds.

Variable rheology agents

The composition to be injected according to the invention can be a composition comprising at least one agent with variable rheology. The viscosity of this composition then increases between the time when the composition is prepared and a moment after the injection, after it has reached its destination site in the skin.

The viscosity may be increased by gelation or by any other physical phenomenon causing particles or molecules of the composition to agglomerate, for example under the effect of electrostatic forces or of coalescence, which leads to creating a kind network or mesh.

The aggregation process can be triggered by heat, when the temperature of the composition increases above a certain value, which is preferably chosen to be close to 37 ° C. Thus, the composition when injected may have a lower viscosity than that which it then takes in situ in the skin where it was injected. Its injection is facilitated without affecting its performance to fill skin defects.

The composition can be a liquid composition containing particles in the dispersed state in a liquid medium, said composition being able to solidify by the aggregation of the particles.

The composition can comprise at least one biopolymer, preferably an alginate, and an ion solution, in particular a solution of divalent ions. The viscosity of the biopolymer advantageously increases in the skin, by gelation of the biopolymer, until the latter becomes solid. Due to the mechanism of aggregation of biopolymers and their injection into quantities and depths within the skin that cannot be reached by the use of topical compositions, lasting and visible effects can be obtained.

One of the biopolymers considered according to the invention may be the Novabel® alginate from the company Merz, which can be absorbed in 3 to 6 months.

In a preferred embodiment, the composition comprises a sodium alginate and a solution of a calcium salt, preferably a solution of calcium carbonate CaCCh. The improved reactivity of alginates with calcium ions has been described in the article by B. Larsen et al. Rheological characterization of an injectable alginate gel system, BMC Biotechnology 2015, pages 15-29. A solution of active compounds, such as a solution of calcium carbonate, makes it possible, by transporting ionic energy, to generate in situ a precipitate forming a film or a lattice in the layers of the skin.

A particularly suitable sodium alginate is derived from brown algae and can be an injectable polymer powder FMC® solubilized in water. One such compound is a hydrophilic colloid, or hydrocolloid, defined as a colloid system in which the colloidal particles are hydrophilic polymers dispersed in water.

The biopolymer and the ion solution can be mixed before packaging in the cartridge. Alternatively, the biopolymer and the ion solution are contained in different reservoirs and injected separately and successively. The aggregation of the composition is advantageously triggered by heat, once injected into the skin.

The composition can be absorbable, semi-absorbable or non-absorbable.

Composition for treating and / or preventing a color disorder of a skin area

Skin coloring agents

The composition according to the invention can be a composition comprising at least one agent for coloring the skin.

The coloring agent can be melanin.

The coloring agent can be chosen from pigments, in particular interferential pigments, and dyes, in particular water-soluble or liposoluble.

The presence of at least one skin coloring agent within the composition makes it possible to correct a color disorder or to make a long-lasting or permanent makeup.

The pigments useful in the present invention can be in the form of powder or pigment paste.

The term “dyes” should be understood to mean compounds, generally organic, which are soluble in at least one oil, in an aqueous-alcoholic phase or in water.

By "pigments" is meant white or colored, mineral, organic or mineral / organic composite particles, insoluble in an aqueous or oily medium, intended to color and / or opacify.

By “interference pigments”, it is necessary to understand colored particles of any shape, iridescent or not, preferably synthesized and which exhibit a color effect by optical interference, for example a Mica / TiCL pigment, ie a mica particle covered with a layer of titanium oxide T1O2 of controlled thickness.

The composition may comprise an aqueous phase and at least one pigment, in particular chosen from mineral or organic pigments, and in particular from non-lamellar mineral pigments.

The aqueous phase can represent at least 50% of the total weight of the composition.

Preferably, the pigment is a pigment approved by the CTFA for its use in cosmetics and by the FDA for its use in cosmetic formulations.

Metallic oxides such as iron oxides (especially those of yellow, red, brown, black color), titanium dioxides, aluminum oxide, zinc oxide, cerium oxide can be used as pigments. , zirconium oxide, chromium oxide, composite oxides; manganese violet, blue ultramarine, prussian blue, ultramarine blue, ferric blue and their mixtures.

In a variant, the pigment used is an organic pigment chosen from synthetic or natural pigments, in particular from FD&C and D&C pigments. The organic pigment can also be a diketopyrrolopyrrole (DPP) as described in the publications EP-A-542669, EP-A-787730, EP-A-787731 and WO-A- 96/08537.

The composition is, for example, one of the solutions of bio-pigments BioChromaDerm® or BioChromaEyes® from the company Biotic Phocea.

The composition may include a liposoluble or water-soluble dye.

The liposoluble dyes are for example chosen from Sudan red, DC Red 17, DC Green 6, β-carotene, soybean oil, Sudan brown, DC Yellow 11, DC Violet 2, DC orange 5, quinoline yellow and their mixtures.

The water-soluble dyes are, for example, chosen from beet juice and methylene blue and their mixtures.

The composition may further comprise fillers with a high refractive index or reflective particles or particles modifying the path of the light to prevent reflection.

The composition may in particular comprise at least one coloring agent chosen from (and their mixtures):

Color Trade name Usual name Name of supplier Chemical name Black SUNPURO BLACK IRON OXIDE C33-7001 IRON OXIDE SUN BLACK IRON OXIDE Black UNIPURE TRIPLE BLACK LC990 IRON OXIDE SENSIENT BLACK IRON OXIDE Black UNIPURE BLACK LC902 CARBON BLACK Sensient Carbon black (Cl: 77266) D&C Black 2 (nano powder form never coded) difficult to disperse without grinding Black WD-CB2 CARBON BLACK Daito 25% CB dip Water and PEG-40 hydrogenated castor oil and LAURETH-21 and SODIUM DEHYDROCETATE and Carbon black (D&C BLACK 2) Black BLACK NF IRON OXIDE KOBO BLACK IRON OXIDE (Cl: 77499) Blue SUNCROMA IRON BLUE C38- 5410 FERRIC ferrocyanide SUN FERRIC BLUE Blue UNIPURE BLUE LC 621 BLUE 1 LAKE SENSIENT BLUE ALUMINUM LACQUER BRILLIANT FCF ON ALUMINA (12/88) Blue UNIPURE BLUE LC 686 ULTRAMARINE BLUE SENSIENT OUTREMER BLUE (Cl: 77007) and SILICA Blue UNIPURE BLUE LC 520 CARMINE Sensient Carmine Blue Bordeaux SUNCROMA D&C RED 34 CA LAKE C 24-012 RED 34 LAKE SUN CALCIUM LACQUER FROM BORDEAUX B ON COLOPHANE Green UNIPURE GREEN LC 788 CHROMIUM OXIDE GREEN SENSIENT GREEN CHROME OXIDE Anhydrous Orange SUNCROMA FD&C YELLOW 6 AL LAKE C70-5270 YELLOW 6 LAKE SUN YELLOW ALUMINUM LACQUER BRILLIANT FCF ON ALUMINA (42/58) Pink SUNCROMA D&C RED 28 AL LAKE C14-6623 RED 28 LAKE SUN PHLOXIN B SODIUM SALT ALUMINUM LACQUER ON ALUMINA, ALUMINUM BENZOATE Pink DELL RED C-14-6634 / SUNCROMA D&C RED 22 AL LAKE C14-6634 RED 22 LAKE SUN EOSINE G ALUMINUM LACQUER ON ALUMINUM BENZOATE Pink UNIPURE PINK LC 589 ULTRAMARINES SENSIENT OUTREMER ROSE (Cl: 77007) Red UNIPURE RED LC 3079 OR RED 7 SENSIENT RED CALCIUM SALT LITHOL B Red CARMIN COVALAC W 3508 / COSMETIC CARMINE 09350 / CARMIN RMAM 52% CARMINE FEEL / EUSA COLORS CARMINE ALUMINUM LACQUER OF COCHENILLE Red UNIPURE RED LC 320 CARMIHPC 54% CARMINE FEEL / EUSA COLORS CARMINE ALUMINUM LACQUER OF COCHENILLE

Red SUNCROMA D&C RED 6 BA LAKE C-19-012 RED 6 LAKE SUN RED BARIUM LACQUER LITHOL B ON SULPHATE BARYUM (42/58) Red SUNCROMA D&C RED 6 NA SALT C19-6619 RED 6 NA SALT SUN RED DI-SODIUM SALT LITHOL B (Cl: 15850) Red SUNCROMA D&C RED 7 CA LAKE C-19-003 RED 7 LAKE SUN RED CALCIUM LACQUER LITHOL B ON SULPHATE BARIUM (60/40) Red SUNCROMA D&C RED 7 CA LAKE C 19-011 RED 7 LAKE SUN LITHOL B RED CALCIUM LACQUER ON BARIUM SULPHATE AND COLOPHANE) (40/60) (Cl: 15850: 1 + 77120) Red SUNCROMA D&C RED 7 CA LAKE C19-025 RED 7 LAKE SUN LITHOL B RED CALCIUM LACQUER ON BARIUM SULPHATE AND COLOPHANE (47/5/48) (Cl: 15850: 1 + 77120) Red SUNCROMA D&C RED 30AL LAKE C37-038 RED 30 LAKE SUN RED 30 ALUMINUM LACQUER (Cl 73360) Red SUNCROMA D&C RED 33 AL LAKE C17-6444 RED 33 LAKE SUN DIAMOND SALT ALUMINUM LACQUER ACID D FUCHSIN SODIUM (Cl: 17200) Red SUNCROMA FD&C RED 40 AL LAKE C37-6340 RED 40 LAKE SUN RED ALUMINUM LACQUER ALLURA ON ALUMINA (40/60) Red SUNPURO RED IRON OXIDE C33- 8001 IRON OXIDE SUN RED IRON OXIDE Red UNIPURE RED LC 383 IRON OXIDE SENSIENT RED IRON OXIDE Purple UNIPURE VIOLET LC 581 MANGANESE PURPLE SENSIENT MANGANESE AMMONIUM PYROPHOSPHATE (Cl: 77742) Purple UNIPURE VIOLET LC 587 ULTRAMARINE PURPLE SENSIENT OUTREMER PURPLE (Cl: 77007) Purple UNIPURE BLUE LC 520 CARMINE SENSIENT ANTHRAQUINONIC LAKE PIGMENT (CARMINE Cl 75470) White HOMBITAN ANATASE FF PHARMA TITANIUM DIOXIDE Sachtleben TITANIUM OXIDE (ANATASE NO TREATY) (Cl: 77891) White HOMBITAN AFDC300 (used for NAI-TAO) TITANIUM DIOXIDE Sachtleben TITANIUM (and) ALUMINA DIOXIDE (and) GLYCERINE White TIPAQUE PF-671 TITANIUM DIOXIDE Ishihara SANGYO TREATED RUTILE TITANIUM OXIDE ALUMINA / SILICA / TRI- METHYOLPROPANE (Cl: 77891) White TIPAQUE PFC407 TITANIUM DIOXIDE Ishihara SANGYO TITANIUM DIOXIDE (and) ALUMINUM HYDROXIDE White SACHTLEBEN RC 402 TITANIUM DIOXIDE Hunstman RUTILE TITANIUM OXIDE (Cl: 77891) White KRONOS 1171 (used ΝΑΙ TAO) TITANIUM DIOXIDE KRONOS TITANIUM OXIDE (ANATASE NO TREATY) (Cl: 77891) White TIPACUE CR-50 TITANIUM DIOXIDE Ishihara SANGYO TITANIUM OXIDE (Cl: 77891) RUTILE Yellow SUNCROMA FD&C YEL 5 AL LK C69-4424 YELLOW 5 LAKE SUN ALUMINUM LACQUER TARTRAZINE ON ALUMINA (26/74) Yellow FD&C YEL 5 AL W001 YELLOW 5 LAKE SENSIENT ALUMINUM SALT OF YELLOW 5 ABSORBED ON ALUMINA GEL (DYE CONTENTS 25%)

Yellow SUNCROMA FD&C YEL 5 AL LK C69002 YELLOW 5 LAKE SUN ALUMINUM LACQUER TARTRAZINE ON ALUMINA (15/85) (Cl: 19140: 1 + 77002) Yellow UNIPURE YELLOW LC124 YELLOW 10 LAKE SENSIENT YELLOW 10 LAKE Yellow SUNPURO YELLOW IRON OXIDE C33-9001 IRON OXIDE SUN YELLOW IRON OXIDE Yellow SUNCROMA FD&C YELLOW 6 AL LAKE C70-5270 YELLOW 6 LAKE SUN YELLOW ALUMINUM LACQUER BRILLIANT FCF ON ALUMINA (42/58) (Cl: 15985: 1 + 77002)

additives

The composition according to the invention can comprise at least one usual cosmetic ingredient other than a filling agent or a coloring agent, which can be chosen in particular from antioxidants, sun filters, vitamins, moisturizers, anti-wrinkle active agents. , emollients, hydrophilic or lipophilic active agents, anti-free radical agents and their mixtures.

In the long term, injecting the composition into human keratin materials can stimulate the user's own collagen production by the collagen producing cells. Lasting effects can thus be observed, in particular the filling of fine lines and / or wrinkles of the skin.

The invention will be better understood on reading the detailed description which follows, of an example of non-limiting implementation thereof, and on examining the appended drawing, in which:

- Figure 1 shows schematically and in perspective an example of cartridge according to the invention,

FIG. 2 is a longitudinal section in the plane A of FIG. 1,

FIG. 3 represents a longitudinal section in plane A of FIG. 1, without the push rod,

FIG. 4 shows schematically and in perspective an example of an injection system according to the invention, FIG. 5 is a longitudinal section along plane B of FIG. 4,

FIG. 6 schematically represents an example of an injection system according to the invention, and

- Figure 7 shows a detail of a variant cartridge in elevation.

Cartridge

FIG. 1 shows an example of a cartridge 1 for a needleless injection device according to the invention.

The cartridge 1 generally extends along an axis X. It comprises a body 2 having a cylindrical portion 2a having at one end 3 an opening 3a.

The cylindrical portion 2a is extended opposite the end 3 by a frustoconical portion 2b forming an injection nozzle 6. The cartridge 1 is configured to be mounted on an injection device, not visible in FIG. 1. The injection nozzle 6 has an outlet channel 6a and an end face 6b to be positioned facing or in contact with the human keratin materials to be treated.

As shown in Figure 2, the cartridge 1 has a first chamber 5 for receiving the composition C to be injected. The channel 6a of the injection nozzle 6 communicates with this first chamber 5.

A second chamber 7, containing a composition reserve, communicates with the first chamber 5 by at least one supply duct 8.

In the example illustrated, the first chamber 5 occupies a central position in the cartridge 1, and has a first portion 5a, cylindrical, of cross section SI, and a second portion 5c, cylindrical, of cross section S2, smaller than the SI section. The first and second portions 5a and 5c are connected by an intermediate portion 5b converging towards the distal end of the cartridge 1. The first chamber 5 has a distal portion 5d whose wall converges towards the distal end of the cartridge 1, this portion 5d forming the bottom of the first chamber 5. The latter may have, as illustrated, a circular cross section over its entire length.

The outlet channel 6a can have a constant cross section, for example circular, over its entire length.

As a variant, the injection nozzle 6 comprises several outlet channels 6a, each one being connected to the bottom 5d of the first chamber 5 and each opening at the end of the nozzle by a corresponding opening 6c.

The opening 6c of the or each outlet channel 6a of the injection nozzle 6 can be covered before the first use of a removable cover (not shown), which adheres to the end of the injection nozzle 6. This seal ensures the preservation and sterility of the composition C contained in the cartridge 1.

The first chamber 5 receives a first piston 9, the distal end 9a of which has a conical shape, complementary to that of the bottom 5d of the first chamber 5. This first piston 9 can be made of an elastomeric material.

The first piston 9 is applied sealingly against the internal surface of the portion 5c of the first chamber 5, and may include one or more annular sealing lips, for example as illustrated two lips 9b and 9c.

The cartridge 1 may include a push rod 10, the distal end 10a of which is fixed by snap-fastening, screwing, friction and / or any other means to the first piston 9. The rod 10 comprises at its proximal end a head 10b configured to cooperate with an injection device drive system.

The cartridge 1 is arranged so that the first piston 9 slides within the first chamber 5, along its longitudinal axis, driven by the push rod 10.

As a variant, the cartridge 1 does not have a first piston 9 or a push rod 10, as illustrated in FIG. 3. The first piston 9 can then be fixed on the distal end 10a of the push rod 10. The opening of the first chamber 5 at the proximal end 3 of the cartridge 1 can be covered before the first use of a removable cover (not shown) which adheres to the proximal end 3 of the cartridge

1. This cover ensures the preservation and sterility of the composition C contained in the cartridge 1.

The second chamber 7 can be annular in shape and extend around the first chamber 5, as illustrated. Preferably, the volume of the second chamber 7 is greater than that of the first chamber 5.

The second chamber 7 communicates with the first chamber 5 via a supply duct 8. The latter can be perpendicular to the axis of the chamber 5, as illustrated, or oblique up or down.

This conduit 8 is equipped with a valve 11 which opens in the direction of circulation of the composition from the second chamber 7 to the first 5. This valve has no spring to call to rest the shutter 12 , here constituted by a ball.

As a variant, the second chamber 7 communicates with the first chamber 5 via several supply conduits 8. This allows better transfer of the composition from the second chamber 7 to the first chamber 5, in particular a faster transfer.

The second chamber 7 is closed at one of its ends by a second piston 14 which is, in the example considered, of annular shape. This second piston 14 is applied sealingly against the inner wall 7a of the second chamber 7. It may have one or more sealing lips 14a and 14b.

The second piston 14 can be driven by any means in the direction of emptying the second chamber 7.

The first chamber 5, the second chamber 7, the injection nozzle 6 and the supply conduit 8 can be formed within a single piece. Alternatively, they are formed by assembling several components.

The cartridge 1 can be made of a thermoplastic material, in particular based on polycarbonate. The elements of the cartridge 1 in contact with the composition C to be injected, in particular the wall of the first chamber 5, of the second chamber 7, of the supply duct 8 and of the outlet channel 6a, can be covered with glass, in particular silicone and / or depyrogenated.

Alternatively, if the viscosity of the composition allows, the radially outer wall 20 of the cartridge 1 is made of a flexible deformable material. This then allows the user to supply the first chamber 5 with the composition C contained in the second chamber 7 by applying pressure to the wall 20, for example with his fingers.

In another variant, the cartridge includes a visual indicator of the degree of emptying of the composition C contained in the second chamber 7, for example a transparent window made in the wall 20.

The cartridge can be specifically dedicated to a particular application, in particular the treatment and / or prevention of folds on the surface of the skin, for example folds of the labio-nasal area (also called nasolabial folds), crow's feet area, the area between the eyebrows and / or the forehead area. The cartridge can be dedicated for use on fine lines, surface wrinkles and / or deep wrinkles.

The nature of the active compound present in the composition to be injected, the volumes and dimensions of the first and second chambers and of the injection nozzle are adapted to the intended application and to the physicochemical properties of the composition, such as the particle size when the composition is a loose powder or viscosity when the composition is liquid.

As a variant, the cartridge 1 comprises several second chambers. Each second chamber communicates with the first chamber through at least one supply duct. Each second chamber can be tubular in shape and be arranged outside the first chamber, being closed at its proximal end by a second corresponding piston. These second chambers can all contain the same composition C to be injected. Alternatively, the second chambers contain different compositions. This allows the same cartridge 1 to be used in several applications. If applicable, at least one of the second chambers contains a cleaning product to replace a composition C to be injected. This makes it possible to clean the cartridge 1, in particular the injection nozzle 6, between two injections of different compositions. The cleaning solution may be chosen from one of the solvents of the composition to be injected in order to be compatible with it, and include isodecane, a volatile silicone or also alcohol or water.

The cartridge can be removable and replaceable.

The cartridge can be refillable or not.

The cartridge may include means for heating the composition C to be injected or the area of human keratin materials to be treated.

The section and the radius of curvature of the end face 6b of the injection nozzle 6 are chosen, where appropriate, as a function of the type of keratin materials treated, the face 6b then being applied directly in contact with the keratin materials treated. The radius of curvature can be chosen so as to substantially match the curvature of the treated area. This makes it easier to apply the injection system to certain body surfaces. For example, the face 6b has a concave shape towards the outside.

Several cartridges 1 having nozzles of different shapes can be offered to the user for mounting on the injection device. This makes it possible to choose a cartridge 1 having the injection nozzle of the most suitable shape for the area of keratin materials to be treated.

In a variant not illustrated, the cartridge comprises several first chambers 5 equipped with their respective pistons, so as to allow several injections in parallel, simultaneously or sequentially. These first chambers can be supplied by the same second chamber, or by respective second chambers. All of the above description, of an exemplary embodiment comprising only one first chamber 5, also applies to a variant with several first chambers.

As illustrated in FIG. 7, the cartridge 1 may include a third chamber 60 arranged in the extension of the injection nozzle 6, on the exit path of the composition. This third chamber 60 has an outlet orifice (not shown) through which the composition to be injected is expelled to the outside. This third chamber 60 can be subjected to a pressure below atmospheric pressure, by being connected for example to a vacuum source (not shown). This makes it possible to increase, during the injection, the speed with which the composition is ejected from the nozzle in the direction of the skin, so as to allow the composition to at least partially penetrate the skin.

Needle-free injection device

The injection system 150 according to the invention, shown in FIG. 4 in particular, comprises the cartridge 1 according to the invention described above and an injection device 100.

The cartridge 1 is configured to come into contact, and in particular to be inserted, into the injection device 100. The cartridge 1 can be fixed by any means to the injection device 100.

The injection device 100 may include a housing 101 made of a thermoplastic material, in particular based on polycarbonate.

The housing 101 can be given different shapes.

Preferably, the housing 101 has an elongated shape to facilitate its handling and its manipulation.

The housing 101 may include a first portion 101a which is fixed to the cartridge 1 and a second portion 101b in the extension of the first, of larger cross section and of greater length than the latter.

As illustrated in FIG. 5, the first portion 101a of the housing 101 may comprise at its distal end a nozzle 104 configured to engage in the proximal portion 5a of the first chamber 5.

The injection device 100 may comprise any propulsion means making it possible to expel the composition C contained in the cartridge 1 towards the outside through the opening (s) 6c of the injection nozzle 6.

This propulsion means can be actuated by a gas, and include a first actuator 103 configured to slide within a housing 106 along the longitudinal axis of the injection device 100.

The source of pressurized gas can be a gas cartridge 102, received in a housing 105 in the second portion 101b of the housing 101. The gas cartridge 102 can be removable and / or refillable.

As illustrated in FIG. 6, the injection device 100 may comprise a regulation and control system 140 of the gas cartridge 102, comprising for example a solenoid valve and / or a regulator. This control system 140 can allow the delivery of gas pulses. The control system 140 can make it possible to regulate parameters such as the pressure, the flow rate, the duration and the frequency of the gas pulses.

The control system 140 can be electrically connected to a power supply 160. The role of the power supply 160 is to supply electrical energy to the control system so that the latter can operate. The power supply 160 may be a battery or a battery, in particular a rechargeable battery, a mains supply, or any other source of electrical supply.

The gas cartridge 102 can enable the first actuator 103 to be driven to forcefully expel the composition C contained in the first chamber 5 in keratin materials and, if necessary, to drive the second actuator 109 to push the reserve of composition C contained in the second chamber 7 towards the first chamber 5 so as to recharge the latter.

The gas used can be air, nitrogen, CO2, or any other propellant.

As a variant, the first actuator 103 is actuated by an electromagnet or a spring whose compression can be manual or motorized.

The first actuator 103 may comprise, as illustrated in FIG. 5, at least one elastic return member 111 configured so as to assist the movement of the first actuator 103 during injection or on the contrary to dampen this movement or to help the actuator to return to its initial position after injection.

The first actuator 103 has at its distal end a head 103a connected by a coupler 107 to the push rod 10.

The injection device 100 may include a second actuator 109 configured to slide the second piston 14 within the second chamber 7 along the longitudinal axis of the injection device 100. This allows the first chamber 5 to be supplied by the composition C contained in the second chamber 7.

The second actuator 109 can be biased by a spring actuation mechanism 110. As a variant, the second actuator 109 is moved by any other actuation means. For example, the second actuator 109 is actuated by a source of pressurized gas, and in particular by the gas cartridge 102.

The second actuator 109 may be of annular shape.

The cartridge 1 may alternatively include several second chambers 7, arranged all around the first chamber 5 and each closed by a second piston at its proximal end. The cartridge 1 can be rotatably mounted on the injection device 100. The rotation of the cartridge 1 on the injection device allows the second actuator 109 to be aligned with one of the second chambers according to a carousel-type arrangement . This rotation can be done manually or motorized. This allows the user to be able to choose with which of the second chambers 7 he wishes to supply the first chamber 5.

In another variant, the device comprises several second actuators 109.

The injection can be triggered by a user action on a control member such as a push button for example.

The housing 101 can thus include a push button (not shown) which allows the user, by pressing it, to initiate the injection.

The supply of the first chamber 5 by the reserve of composition C contained in the second chamber 7 can also be carried out if necessary by means of an element which can be actuated by the user.

The device 100 can be offered to the user, with one or more cartridges 1 containing one or more compositions to be injected, for example into a common package, these cartridges may each have a nozzle specific to the type of treatment to be performed.

The injection device 100 can constitute a portable and autonomous system.

The injection device 100 may include, if necessary, a system for recognizing the cartridge 1, for example by means of an electromechanical probe, electrical contacts or an electronic chip. For example, the cartridge 1 comprises an RFID chip which is read by the injection device 100. The cartridge 1 can thus be automatically recognized by the injection device 100. Knowledge by the device of the cartridge in place can allow automatically adapt operating parameters of the device, for example the pressure, the duration, the flow and / or the frequency of the gas pulses leaving the gas cartridge.

In a variant, the operation and / or the configuration of the injection system 10 150 is controlled remotely, for example with a smartphone. The injection system 150 then includes a wireless communication interface.

The invention is not limited to the examples which have just been described. For example, in a variant, the injection device does not include a first piston for pressurizing the contents of the first chamber.

The term "comprising" must be understood with its current acceptance, that is to say as being synonymous with "comprising at least one", unless otherwise specified.

Claims (15)

1. Cartridge (1) for an injection device (100) without needle comprising: - at least one first chamber (5) containing and / or intended to receive a composition (C) to be injected, - at least one injection nozzle (6) communicating with the or each first chamber (5), the cartridge comprising several first chambers (5) and / or the cartridge comprising at least a second chamber (7) containing the composition (C ) to be injected and communicating with the first chamber or chambers (5) by at least one supply duct (8) through which the supply of the first chamber or chambers (5) is carried out with the composition (C) contained in the or each second chamber (7). 2. Cartridge according to claim 1, the or each supply duct (8) comprising a shutter (12), the latter closing the or each supply duct (8) during the injection and opening it between two injections for filling the or each first chamber (5). 3. Cartridge according to claim 1 or 2, the or each first chamber (5) receiving a first piston (9) connected to a push rod (10), the first piston (9) sliding along the longitudinal axis of the first chamber (5) being driven by the push rod (10). 4. Cartridge according to any one of the preceding claims, the volume of the or each first chamber (5) being less than that of the second chamber (O- 5. Cartridge according to any one of the preceding claims, the second chamber (7) being of annular shape and extending around the first. 6. Cartridge according to any one of the preceding claims, comprising a third chamber (60) arranged in the extension of the injection nozzle (6), this chamber being subjected to a pressure below atmospheric pressure. 7. Cartridge according to any one of the preceding claims, the or each second chamber (7) being closed at one of its ends by a second piston (14), in particular of annular shape, sliding along the longitudinal axis of the or each second chamber (7). 8. Cartridge according to any one of the preceding claims, the composition (C) being liquid and comprising a liquid phase, a mixture of a liquid phase and a pulverulent phase, a mixture of a liquid phase and a gas phase, or a mixture of a liquid, pulverulent and gaseous phase. 9. Cartridge according to claim 8, the composition (C) having, at least at the time of its injection, a viscosity greater than or equal to 10 Pa.s at 25 ° C and at atmospheric pressure. 10. Cartridge according to claim 8 or 9, the composition (C) comprising a dispersion of particles in a liquid medium, said composition being solidifiable via the aggregation of said particles. 11. Cartridge according to claim 10, the composition (C) comprising at least one biopolymer, in particular an alginate, and an ionic solution, in particular a solution of a divalent ion. 12. Cartridge according to any one of the preceding claims, the composition (C) comprising at least one filling agent, in particular a biopolymer such as hyaluronic acid and / or one of its salts, particles of hydroxyapatite, polylactic acid, alginate, sodium monomethyltrisilanol orthohydroxy benzoate, collagen, an acrylic polymer such as polyacrilamide, a methacrylic polymer and / or dextran microbubbles. 13. Cartridge according to any one of the preceding claims, the composition (C) comprising at least one agent for coloring the skin, in particular chosen from pigments, in particular interferential pigments, and dyes, in particular water-soluble or liposoluble. 14. A needle-less injection system (150) comprising a cartridge (1) according to any one of the preceding claims, and a needle-less injection device (100) for actuating the cartridge (1). 15. Process for cosmetic, non-therapeutic treatment of human keratin materials, comprising the steps consisting in: - arranging a cartridge (1) containing a composition (C) to be injected into an injection device (100) without needle so as to form an injection system (150) without needle according to claim 14, approach the system injection (150) without needle of the human keratin materials to be treated, delivering each injection into said human keratin materials, an amount of the composition (C) contained in the cartridge (1).